Search our Database of Scientific Publications and Authors

I’m looking for a

    123 results match your criteria Spontaneous Primary Ovarian Insufficiency and Premature Ovarian Failure

    1 OF 3

    Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency.
    • Authors:
    Obstet Gynecol 2017 05;129(5):e134-e141
    Primary ovarian insufficiency describes a spectrum of declining ovarian function and reduced fecundity due to a premature decrease in initial follicle number, an increase in follicle destruction, or poor follicular response to gonadotropins. The sequelae of primary ovarian insufficiency include vasomotor symptoms, urogenital atrophy, osteoporosis and fracture, cardiovascular disease, and increased all-cause mortality. In women with primary ovarian insufficiency, systemic hormone therapy (HT) is an effective approach to treat the symptoms of hypoestrogenism and mitigate long-term health risks if there are no contraindications to treatment. Read More

    Committee Opinion No. 698 Summary: Hormone Therapy in Primary Ovarian Insufficiency.
    • Authors:
    Obstet Gynecol 2017 May;129(5):963-964
    Primary ovarian insufficiency describes a spectrum of declining ovarian function and reduced fecundity due to a premature decrease in initial follicle number, an increase in follicle destruction, or poor follicular response to gonadotropins. The sequelae of primary ovarian insufficiency include vasomotor symptoms, urogenital atrophy, osteoporosis and fracture, cardiovascular disease, and increased all-cause mortality. In women with primary ovarian insufficiency, systemic hormone therapy (HT) is an effective approach to treat the symptoms of hypoestrogenism and mitigate long-term health risks if there are no contraindications to treatment. Read More

    Autoimmune polyglandular syndrome type 3 (APS-3) among patients with premature ovarian insufficiency (POI).
    Eur J Obstet Gynecol Reprod Biol 2016 Aug 20;203:61-5. Epub 2016 May 20.
    Department of Gyneacological Endocrinology, Medical University of Warsaw, Ul. Karowa 2, 00-315 Warsaw, Poland.
    Objectives: Autoimmune polyglandular syndrome type 3 - (APS-3), is defined as the coexistence of autoimmune thyroiditis with other non-ovarian autoimmune diseases without primary adrenal insufficiency. Additionally the definition of APS-3 also includes primary ovarian insufficiency (POI) coexistence with autoimmune thyroiditis. The main goal of that study is to assess the prevalence of APS-3 defined as coexistence of autoimmune thyroiditis with POI in population of 46 XX karyotype women with primary ovarian insufficiency (POI). Read More

    Premature ovarian insufficiency: the context of long-term effects.
    J Endocrinol Invest 2016 Sep 18;39(9):983-90. Epub 2016 Apr 18.
    Department of Gynecological Endocrinology, Poznan University of Medical Sciences, ul. Polna 33, Poznan, Poland.
    Purpose: Premature ovarian insufficiency (POI) is defined as the cessation of the ovarian function before the age of 40 years. POI aetiology may be related to iatrogenic or endogenous factors and in many cases remains unclear. The aim of this review was to characterize the long-term consequences of POI. Read More

    Analysis of FMR1 gene premutation and X chromosome cytogenetic abnormalities in 100 Tunisian patients presenting premature ovarian failure.
    Ann Endocrinol (Paris) 2015 Dec 1;76(6):671-8. Epub 2015 Dec 1.
    Laboratory of human cytogenetics, molecular genetics and reproductive biology, Farhat Hached university hospital, street Ibn El Jazzar, 4000 Sousse, Tunisia.
    Objective: To evaluate the prevalence of FMR1 premutations and X chromosome cytogenetic abnormalities in a large cohort of Tunisian women with premature ovarian failure (POF).

    Patients And Methods: The cohort consisted of 127 Tunisian women with POF referred by endocrinologists and gynecologists for genetic investigation in the context of idiopathic POF and altered hormonal profiles. Clinical information concerning the reproductive function in the family, previous hormonal measurements and/or possible fertility treatment were collected. Read More

    Effect of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis.
    Climacteric 2016 17;19(1):27-36. Epub 2015 Nov 17.
    a Department of Maternal and Child Health, School of Public Health , Anhui Medical University , Hefei ;
    Objective: The aim of this review was to systematically evaluate the associations of all-cause, cardiovascular and all-cancer mortality with primary ovarian insufficiency (POI) and early natural menopause (ENM).

    Methods: Electronic databases for relevant studies were searched up to February 28, 2015. POI and ENM were usually defined as spontaneous menopause before age 40 years and at age 40-44 years, respectively. Read More

    Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
    Oncologist 2015 Nov 13;20(11):1283-9. Epub 2015 Oct 13.
    Department of Hematology, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
    Background: The use of gonadotropin-releasing hormone analogs (GnRHas) for fertility preservation is not unequivocally accepted. It is controversial whether GnRHa can increase the pregnancy rate in survivors.

    Patients And Methods: This is a retrospective cohort study. Read More

    Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis.
    Obstet Gynecol 2015 Jul;126(1):187-95
    Departments of Obstetrics and Gynecology, Zagazig University School of Medicine, Zagazig, and Cairo University Faculty of Medicine, El Manial, Cairo, Egypt; and the Department of Obstetrics and Gynecology, Maastricht University, Maastricht, the Netherlands.
    Objective: To estimate whether gonadotropin-releasing hormone (GnRH) analog administration during chemotherapy can protect against development of ovarian toxicity.

    Data Sources: MEDLINE (1966 to present), EMBASE (1980 to present), Cochrane Central Register of Controlled Trials (CENTRAL), World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov were searched through March 2015 using the phrases: "gonadotropin-releasing hormone," "chemotherapy," and "premature ovarian failure. Read More

    Spontaneous Recovery of Ovarian Function in an Adolescent with Galactosemia and Apparent Premature Ovarian Insufficiency.
    J Pediatr Adolesc Gynecol 2015 Aug 16;28(4):e101-3. Epub 2014 Sep 16.
    Department of Obstetrics and Gynecology, Queens University, Kingston, Ontario, Canada. Electronic address:
    Background: Galactosemia is an inborn error of metabolism resulting in premature ovarian insufficiency in 80-90% of females. There have been no reported cases of biochemical ovarian failure followed by normal menses.

    Case: A 12-year-old girl with galactosemia presented for gynecologic consultation. Read More

    AMH as Predictor of Premature Ovarian Insufficiency: A Longitudinal Study of 120 Turner Syndrome Patients.
    J Clin Endocrinol Metab 2015 Jul 15;100(7):E1030-8. Epub 2015 May 15.
    Department of Gynecology/Fertility Clinic (S.Aa.L., A.T.P.), and Department of Clinical Genetics (L.A.), Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark; Medical Research Council Centre for Reproductive Health (R.A.A.), University of Edinburgh, Edinburgh EH8 9YL, United Kingdom; and Department of Growth and Reproduction and EDMaRC (K.M.M., A.J., C.P.H.), and The Paed-Gyn Endo Transition Clinic (K.M.M., A.J., C.P.H., A.T.P.) at Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.
    Context: The majority of Turner syndrome (TS) patients suffer from accelerated loss of primordial follicles. Low circulating levels of anti-Müllerian hormone (AMH) may predict the lack of spontaneous puberty in prepubertal girls and imminent premature ovarian insufficiency (POI) in TS women with preserved ovarian function.

    Objectives: To evaluate the association between circulating AMH and ovarian status in TS patients. Read More

    The Turner syndrome in patient with 45X/47XXX mosaic karyotype--case report.
    Gynecol Endocrinol 2015 Jul;31(7):526-8
    a Department of Gynecological Endocrinology , Poznan University of Medical Sciences , Poznan , Poland.
    Background: Turner syndrome (TS) is a gonadal dysgenesis related to partial or total lack of one of the X chromosomes. It this report we describe a young patient presenting some somatic features of TS, who underwent spontaneous puberty and was eumenoorheic up to the age of 23.

    Methods: Using fluorescent in situ hybridization (FISH) mosaic karyotype (45X[131]/47XXX[9]) of TS and triple X syndrome was found. Read More

    The prevalence and phenotypic characteristics of spontaneous premature ovarian failure: a general population registry-based study.
    Hum Reprod 2015 May 23;30(5):1229-38. Epub 2015 Feb 23.
    Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, Tartu 50411, Estonia Competence Centre on Health Technologies, Tiigi 61b, Tartu 50410, Estonia Department of Obstetrics and Gynecology, University of Tartu, L. Puusepa 8, Tartu 51014, Estonia.
    Study Question: What is the measured prevalence and phenotype of spontaneous premature ovarian failure (POF) in the general population?

    Summary Answer: Spontaneous POF occurs in ∼1% of the general population with unique phenotype of post-menopausal ageing distinct from surgically induced premature menopause.

    What Is Known Already: POF is multifactorial ovarian quiescence before the age of 40. The clinical features of POF are diverse and the population prevalence of POF is still not known. Read More

    Premature ovarian insufficiency: from pathogenesis to clinical management.
    J Endocrinol Invest 2015 Jun 18;38(6):597-603. Epub 2015 Jan 18.
    Department of Molecular and Developmental Medicine, Obstetrics and Gynecology, University of Siena, Policlinico "Le Scotte" Viale Bracci, 53100, Siena, Italy.
    Premature ovarian insufficiency (POI) represents a condition characterized by the absence of normal ovarian function due to an incipient (by 3-10 years) ovarian aging. In most of the women affected there are no signs or symptoms that precede the interruption of menstruation and the onset of POI and the majority of women have a normal history of menarche, regular menstrual cycles and normal fertility. The possible genetic role in the development of POI has been largely demonstrated and many genes have been involved; on the other hand, ovary is not protected immunologically and the detection of autoantibodies directed against various ovarian targets strongly support the hypothesis of an autoimmune etiology. Read More

    Pituitary mass and subsequent involution causing fluctuations of serum follicle-stimulating hormone levels in a Turner syndrome patient with premature ovarian failure: a case report.
    J Reprod Med 2014 Sep-Oct;59(9-10):504-8
    Background: Premature ovarian failure (POF) is described as estrogen deficiency, amenorrhea, and hypergonadotropinemia in a woman < 40 years old. In a proportion of patients diagnosed with POF, intermittent and unpredictable return of ovarian function can be observed, causing fluctuations of follicle-stimulating hormone (FSH). However, these patients also have return of menstrual cycles. Read More

    Safety and usefulness of cryopreservation of ovarian tissue to preserve fertility: a 12-year retrospective analysis.
    Hum Reprod 2014 Sep 22;29(9):1931-40. Epub 2014 Jun 22.
    Department of Obstetrics and Gynaecology, Fertility Clinic, Université Libre de Bruxelles, Erasme Hospital, Brussels, Belgium Research Laboratory on Human Reproduction, Faculty of Medicine, Université Libre de Bruxelles, Campus Erasme, Brussels, Belgium
    Study Question: Do the benefits of ovarian tissue cryopreservation outweigh the risks for patients seeking to preserve fertility before gonadotoxic treatment in various indications?

    Summary Answer: In >90% of the patients undergoing cryopreservation of ovarian tissue, oncological treatment was associated with a reduced ovarian reserve and in 30% of patients, premature ovarian failure (POF) occurred within 5 years.

    What Is Known Already: Ovarian tissue cryopreservation is an effective fertility preservation option, especially for pre-pubertal patients and patients who have a short time between diagnosis of a disease and gonadotoxic treatment.

    Study Design, Setting, Duration: This study retrospectively analysed ovarian function and fertility recovery rates, as well as ovarian tissue characteristics, of patients who underwent ovarian tissue cryopreservation at Erasme Hospital between 1999 and 2011. Read More

    Premature menopause - Meeting the needs.
    Post Reprod Health 2014 Jun 16;20(2):62-68. Epub 2014 May 16.
    Gynaecworld, The Center for Women's Health and Fertility, Mumbai, Maharashtra, India.
    Premature menopause is characterized by amenorrhea, elevated gonadotropin levels and sex steroid deficiency occurring in women below 40 years of age. Heterogeneity of premature ovarian failure is reflected by various causes, both spontaneous and iatrogenic. X chromosomal abnormalities remain the main cause of primary ovarian insufficiency. Read More

    Intermediate CGG repeat length at the FMR1 locus is not associated with hormonal indicators of ovarian age.
    Menopause 2014 Jul;21(7):740-8
    From the 1Imprints Center, New York State Psychiatric Institute, New York, NY; 2Department of Epidemiology, 3Gertrude H. Sergievsky Center, and 4Department of Biostatistics, Columbia University, New York, NY; 5Department of Obstetrics, Gynecology, and Reproductive Science, The University of Vermont, Burlington, VT; 6Diagnostic Research and Technology Development, Asuragen Inc, Austin, TX; and 7Departments of Genetics and Development and Pediatrics, Columbia University, New York, NY.
    Objective: Premutation and intermediate CGG repeat length at the fragile X mental retardation 1 (FMR1) locus have been associated with premature ovarian failure. We tested whether intermediate length is associated with indicators of ovarian age in a sample of fertile women. Our primary measures of ovarian age were antimüllerian hormone (AMH) and follicle-stimulating hormone (FSH) levels. Read More

    The unusual association of Graves' disease, chronic spontaneous urticaria, and premature ovarian failure: report of a case and HLA haplotype characterization.
    Arq Bras Endocrinol Metabol 2013 Dec;57(9):748-52
    Chronic spontaneous urticaria (CSU), defined as the occurrence of spontaneous wheals for more than six weeks, has been associated with autoimmune diseases. Herein, we report the unusual association of CSU, Graves' disease, and premature ovarian failure. Human leukocyte antigen (HLA) studies were performed. Read More

    Premature ovarian insufficiency: how to improve reproductive outcome?
    Climacteric 2014 Jun 16;17(3):242-6. Epub 2013 Dec 16.
    * West London Menopause & PMS Centre, Chelsea and Westminster Hospital , 369 Fulham Road, London.
    Premature ovarian insufficiency (POI) is a life-changing condition that affects women in their reproductive age. The condition is not necessarily permanent but is associated with intermittent and unpredictable ovarian activity. Hence, spontaneous pregnancies have been reported to be 5-10%. Read More

    Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.
    PLoS One 2013 28;8(11):e80444. Epub 2013 Nov 28.
    Reproductive Medical Center, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, P. R. China.
    Background: Gonadotropin-releasing hormone agonists (GnRHa) might play a role in preserving ovarian function in lymphoma patients by inhibiting chemotherapy-induced ovarian follicular damage. However, studies of its clinical efficacy have reported conflicting results.

    Method: We conducted a meta-analysis to determine the effect of the preservation of ovarian function by administering GnRHa in young patients with lymphoma undergoing chemotherapy. Read More

    [Premature ovarian failures].
    Presse Med 2013 Nov 21;42(11):1500-7. Epub 2013 Oct 21.
    Hôpital Saint-Antoine, endocrinologie de la reproduction, Centre des maladies endocriniennes rares de la croissance (CMERC), 75012 Paris, France.
    Premature ovarian failure (POF) is clinically suspected by amenorrhea and confirmed by an elevated FSH serum level above 40 mUI/L (even 20 mUI/L) twice, in a woman before the age of 40. Prevalence of POF is between 1 to 2% in women. In 90% of cases, no aetiology is identified. Read More

    Infertility today: the management of female medical causes.
    Int J Gynaecol Obstet 2013 Dec 5;123 Suppl 2:S25-30. Epub 2013 Sep 5.
    Universitaetsklinikum Giessen and Marburg GmbH, Standort Giessen, Germany. Electronic address:
    It has to be suspected that some environmentally hazardous substances have genotoxic properties, revealing their reproductive toxicity at a later stage only. Cancer, including childhood cancer, is more common than usually expected. Undesirable side effects of surgery, chemotherapy, and/or radiation can be premature ovarian failure or even premature menopause. Read More

    Dehydroepiandrosterone in women with premature ovarian failure and Hashimoto's thyroiditis.
    Climacteric 2014 Feb 28;17(1):92-6. Epub 2013 Jun 28.
    * Department of Gynecologic Endocrinology and Reproductive Medicine, Medical University of Vienna , Vienna.
    We evaluated dehydroepiandrosterone sulfate (DHEAS) levels in premature ovarian failure (POF) patients with and without Hashimoto's thyroiditis, and the impact of DHEA supplementation on thyroid autoantibodies. In a retrospective case series, we included 67 women with spontaneous POF who received estrogen/gestagen replacement with or without DHEA (30 mg/day) for 3 months. Women who were seropositive for thyroglobulin antibodies and/or thyroperoxidase autoantibodies (n = 30) revealed lower pretherapeutic DHEAS levels (1. Read More

    Translocation t(X;11)(q22;q25) in a woman with premature ovarian failure.
    Sex Dev 2013 16;7(4):216-21. Epub 2013 Feb 16.
    Department of Genetics, Dr. ALMPG Institute of Basic Medical Sciences, University of Madras, Chennai, India.
    Genetic, autoimmune, environmental, iatrogenic, and idiopathic factors are known to cause premature ovarian failure (POF). This report describes an X;11 translocation, t(X;11)(q22;q25), in a woman diagnosed with POF. The FSH level was found to be elevated. Read More

    Fertility in cancer patients after cryopreservation of one ovary.
    Reprod Biomed Online 2013 Mar 13;26(3):272-9. Epub 2012 Dec 13.
    The Fertility Clinic, Copenhagen University Hospital, Rigshospitalet 9, DK-2100 Copenhagen, Denmark.
    This questionnaire study describes the fertility and ovarian function in 143 adult female cancer survivors with only one ovary due to cryopreservation of the other. The women were asked about their ovarian function (as defined by the presence of a spontaneous menstrual cycle), pregnancies and their outcome. The mean follow-up time was 58months after cryopreservation (range 24-129months). Read More

    Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials.
    Breast 2013 Apr 5;22(2):150-7. Epub 2013 Jan 5.
    Department of Oncology, General Hospital of Chinese PLA, Beijing 100853, China.
    Background: While chemotherapy significantly improves the prognosis of breast cancer patients, it also damages otherwise healthy organs, such as the ovaries. Gonadotropin-releasing hormone (GnRH) agonists may have a protective effect against chemotherapy-induced ovarian toxicity in premenopausal women being treated for breast cancer; however, studies of its clinical efficacy have reported conflicting results.

    Objectives: This meta-analysis was designed to assess the collective data from previous studies of GnRH agonists administered concurrently with chemotherapy to prevent chemotherapy-induced ovarian toxicity in premenopausal women with breast cancer. Read More

    Ovarian function and in vitro fertilization (IVF) in Turner syndrome.
    Pediatr Endocrinol Rev 2012 May;9 Suppl 2:713-7
    Karolinska Institutet Karolinska University Hospital K57, SE 141 86 Stockholm, Sweden.
    Normal numbers of oocytes and ovarian follicles develop to the ovaries during the first half of the fetal life. The oocytes then start gradually disappearing. Abnormal meiotic division due to the lack of a paring X-chromosome has been suggested as the causative factor. Read More

    Fragile X premutation RNA is sufficient to cause primary ovarian insufficiency in mice.
    Hum Mol Genet 2012 Dec 21;21(23):5039-47. Epub 2012 Aug 21.
    State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, PR China.
    Spontaneous 46,XX primary ovarian insufficiency (POI), also known as 'premature menopause' or 'premature ovarian failure', refers to ovarian dysfunction that results in a range of abnormalities, from infertility to early menopause as the end stage. The most common known genetic cause of POI is the expansion of a CGG repeat to 55-199 copies (premutation) in the 5' untranslated region in the X-linked fragile X mental retardation 1 (FMR1) gene. POI associated with the FMR1 premutation is referred to as fragile X-associated POI (FXPOI). Read More

    Protein-losing enteropathy and premature ovarian failure in a young woman with systemic lupus erythematosus.
    Lupus 2012 Oct 24;21(11):1237-9. Epub 2012 May 24.
    Division of Allergy, Immunology and Rheumatology and, Department of Medicine, Taipei Medical University Shuang Ho Hospital, Taipei, Taiwan.
    Protein-losing enteropathy (PLE) and autoimmune oophoritis are unusual manifestations of systemic lupus erythematosus (SLE). Autoimmune oophoritis may result in menstrual disturbance and spontaneous premature ovarian failure. However, there is no validated examination to confirm the diagnosis and it is easily neglected in patients with ovarian insufficiency. Read More

    Catastrophic consequences of assisted reproduction: the case of Turner syndrome.
    Semin Reprod Med 2012 Apr 27;30(2):116-22. Epub 2012 Apr 27.
    Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.
    Women with Turner syndrome are generally infertile due to premature ovarian failure. Few may achieve a spontaneous pregnancy, and others may conceive through assisted reproductive technologies including oocyte donation. These pregnancies are high risk due to the medical conditions associated with Turner syndrome. Read More

    Testosterone concentrations, using different assays, in different types of ovarian insufficiency: a systematic review and meta-analysis.
    Hum Reprod Update 2012 Jul 23;18(4):405-19. Epub 2012 Apr 23.
    Department of Reproductive Medicine and Gynaecology, University Medical Centre Utrecht, Heidelberglaan 100, F05.126, PO Box 75500, 3584 CX Utrecht, The Netherlands.
    Background: Increasing age and post-menopausal status are associated with decreasing androgen concentrations in females. Women with premature loss of ovarian function, such as primary ovarian insufficiency (POI) or iatrogenic menopause may be at increased risk for diminished testosterone levels at a relatively young age. Differentiation between a hypoandrogenic or normoandrogenic state in women with premature loss of ovarian function is problematic due to trueness and precision problems using various testosterone assays. Read More

    Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure.
    J Clin Endocrinol Metab 2011 Dec 12;96(12):3864-72. Epub 2011 Oct 12.
    Department of Endocrinology and Reproductive Medicine, Groupe Hospitalier Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
    Context: Resumption of ovarian activity and spontaneous pregnancies are described in patients with premature ovarian failure (POF), but there is a lack of data concerning the prevalence of and predictive factors for these phenomena.

    Objective: The aim of the study was to determine both the prevalence of and predictive factors for spontaneous resumption of ovarian function in POF patients.

    Design And Setting: A mixed retrospective and prospective study was performed at a referral center for reproductive endocrinology. Read More

    Turner syndrome: contemporary thoughts and reproductive issues.
    Semin Reprod Med 2011 Jul 3;29(4):342-52. Epub 2011 Oct 3.
    Department of Obstetrics and Gynecology, Dartmouth Medical School, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, New Hampshire 03756, USA.
    Turner syndrome is a common genetic disorder that has been classically associated with a 45,X karyotype. Several X-chromosomal abnormalities have been identified in these patients, many of which involve mosaicism. These patients have variable but predictable phenotypic findings and are at risk for development of endocrine, autoimmune, and structural abnormalities. Read More

    Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases.
    Semin Arthritis Rheum 2011 Dec 24;41(3):346-52. Epub 2011 Aug 24.
    Reproductive Endocrinology, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
    Objective: Since young women undergoing cyclophosphamide pulse therapy may suffer premature ovarian failure (POF) in almost 50% of cases, we examined the ability of GnRH-a administration to minimize the gonadotoxicity associated with cyclophosphamide pulse therapy (CPT).

    Methods: Retrospective analysis of medical charts of 44 women (age 16-38 years) who received CPT for autoimmune diseases. In 33 patients a monthly depot injection of GnRH-a was started before the alkylating agent. Read More

    Spontaneous pregnancy in a patient with a combination of ovarian and thyroid failure.
    Arq Bras Endocrinol Metabol 2011 Jun;55(4):291-3
    Department of Endocrinology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Kashmir, India.
    Premature ovarian failure has an overall prevalence of 0.3% to 0.9% in general population. Read More

    [Clinical features of women with idiopathic premature ovarian failure].
    Nan Fang Yi Ke Da Xue Xue Bao 2011 May;31(5):886-9
    Department of Gynecology and Obstetrics, Nanfang Hospital of Southern Medical University, Guangzhou, China.
    Objective: To summarize the clinical features of idiopathic premature ovarian failure (POF) and explore the early diagnosis and intervention.

    Methods: A retrospective study was conducted in 39 women with idiopathic POF treated between February, 2009 and January, 2010. The clinical data of the patients including the menstrual feature, POF incidence, vaginal ultrasound and pregnancy outcomes were investigated. Read More

    Autoimmune polyglandular syndrome type 2 induced by treatment with interferon alpha.
    Am J Med Sci 2011 Jun;341(6):504-7
    Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland.
    Interferon α therapy has been reported to result in a variety of autoimmune side effects and to increase the risk of thyroid dysfunction. Autoimmune polyglandular syndromes are rarely described conditions characterized by the combination of at least 2 autoimmune endocrinopathies and nonendocrine autoimmunopathies, differing in the immunologic features of their pathogenesis. In light of research carried out in recent years, it seems that autoimmune polyendocrine syndromes occur much more frequently than previously estimated. Read More

    Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis.
    Fertil Steril 2011 Mar 10;95(3):906-14.e1-4. Epub 2010 Dec 10.
    Department of Obstetrics and Gynecology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
    Objective: To determine whether gonadotropin-releasing hormone (GnRH) analog cotreatment with chemotherapy provides better reproductive outcomes for women at risk of premature ovarian failure (POF) as a side-effect of gonadotoxic chemotherapy.

    Design: Systematic review and meta-analysis.

    Setting: University-affiliated research centers. Read More

    [Breast cancer and subsequent pregnancy. Infertility, death risk and survival].
    Ginecol Obstet Mex 2010 Feb;78(2):85-93
    Servicio de Ginecología Oncológica, Unidad Médica de Alta Especialidad, Hospital de Gineco-obstetricia Núm. 3, Centro Médico Nacional La Raza, IMSS, México, DF.
    Background: The chemotherapy commonly used for the treatment of breast cancer affect the fertility and could cause premature ovarian failure. The subsequent pregnancy to the breast cancer therefore it is not habitual.

    Objective: The purpose of this study was to identify the effects of the chemotherapy in the women reproductive life; to evaluate the frequency of the women that experienced a later pregnancy after treatment of cancer, as well as the effects of the subsequent pregnancy on the breast cancer. Read More

    EMAS position statement: Managing women with premature ovarian failure.
    Maturitas 2010 Sep 3;67(1):91-3. Epub 2010 Jun 3.
    Institute of Endocrinology, Clinical Center of Serbia, Belgrade School of Medicine, Dr Subotica 13, 11000 Beograd,
    Introduction: Premature ovarian failure (also known as premature menopause) is defined as menopause before the age of 40. It can be "natural" or "iatrogenic" such as after bilateral oophorectomy. It may be either primary or secondary. Read More

    What is really responsible for bone loss in spontaneous premature ovarian failure? A new enigma.
    Gynecol Endocrinol 2010 Oct;26(10):755-9
    CLINICAS' Hospital, Gynecology Division, Gynaecological Endocrinology Section, Buenos Aires, República Argentina.
    Objective: To determine if there is a relation between the follicle-stimulating hormone (FSH) and oestradiol levels with values found in bone mineral density, at lumbar spinal and femoral neck levels, in patients with spontaneous premature ovarian failure (POF) as at the time of diagnosis.

    Method: Cross-sectional study. Eighty-five patients were selected with a diagnosis of POF. Read More

    The time is now for a new approach to primary ovarian insufficiency.
    Fertil Steril 2011 May 26;95(6):1890-7. Epub 2010 Feb 26.
    Division of Reproductive Endocrinology and Infertility, Washington University School of Medicine, St. Louis, Missouri, USA.
    Objective: To articulate the need for a new approach to primary ovarian insufficiency. The condition, also known as premature menopause or premature ovarian failure, is defined by the presence of menopausal-level serum gonadotropins in association with irregular menses in adolescent girls or women younger than 40 years. It can be iatrogenic as related to cancer therapy or may arise spontaneously, either alone or as part of a host of ultrarare syndromes. Read More

    Hormone replacement therapy and successful pregnancy in a patient with premature ovarian failure.
    Gynecol Endocrinol 2009 Dec;25(12):769-72
    Gynecology - Obstetrics Clinic 'Narodni front', Belgrade University Medical School, Belgrade, Serbia.
    Premature ovarian failure (POF), premature ovarian insufficiency, premature menopause or hypergonadotropic hypogonadism, a serious life-changing condition that affects young women, remains an enigma and the researcher's challenge. In the present article we described a case of singleton pregnancy in a 33-year-old patient, presenting with POF and treated with hormone replacement therapy. Twenty months later this therapy led to maturation of one follicle, recruitment and fertilisation of the residual oocyte and spontaneous pregnancy ensued. Read More

    IVF outcome in patients with orthotopically transplanted ovarian tissue.
    Hum Reprod 2009 Nov 11;24(11):2778-87. Epub 2009 Aug 11.
    Department of Gynecology, Cliniques Universitaires St Luc, Université Catholique de Louvain, Avenue Hippocrate, 10 B-1200 Brussels, Belgium.
    Background: Chemo- or radiotherapy can induce premature ovarian failure (POF), and ovarian tissue cryopreservation and transplantation may be proposed to restore ovarian function. Our aim was to evaluate the quality of oocytes and embryos derived from frozen-thawed transplanted ovarian tissue.

    Materials And Methods: Women were 21-28 years old at tissue cryopreservation. Read More

    Genome-wide association study in premature ovarian failure patients suggests ADAMTS19 as a possible candidate gene.
    Hum Reprod 2009 Sep 9;24(9):2372-8. Epub 2009 Jun 9.
    Department of Reproductive Medicine and Gynaecology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
    Background: Spontaneous premature ovarian failure (POF) occurs in 1% of women and has major implications for their fertility and health. Besides X chromosomal aberrations and fragile X premutations, no common genetic risk factor has so far been discovered in POF. Using high-density single nucleotide polymorphism (SNP) arrays, we set out to identify new genetic variants involved in this condition. Read More

    Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study.
    J Clin Oncol 2009 May 13;27(14):2374-81. Epub 2009 Apr 13.
    Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105-2794, USA.
    These studies were undertaken to determine the effect, if any, of treatment for cancer diagnosed during childhood or adolescence on ovarian function and reproductive outcomes. We reviewed the frequency of acute ovarian failure, premature menopause, live birth, stillbirth, spontaneous and therapeutic abortion and birth defects in the participants in the Childhood Cancer Survivor Study (CCSS). Acute ovarian failure (AOF) occurred in 6. Read More

    Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients.
    Int J Radiat Oncol Biol Phys 2009 Apr;73(5):1304-12
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA 02115, USA.
    Purpose: Radiation has many potential long-term effects on cancer survivors. Female cancer patients may experience decreased fertility depending on the site irradiated. Oncologists should be aware of these consequences and discuss options for fertility preservation before initiating therapy. Read More

    Spontaneous twin pregnancy in premature ovarian failure.
    Med J Malaysia 2008 Aug;63(3):263-4
    Department of Obstetrics & Gynaecology, Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia.
    Premature Ovarian Failure (POF) is associated with subfertility. Despite efforts to induce ovulation, success rates are low. We report a case of POF spontaneously conceiving twins while on hormone replacement therapy. Read More

    Feasibility of fertility preservation in young females with Turner syndrome.
    Reprod Biomed Online 2009 Feb;18(2):290-5
    Department of Obstetrics and Gynecology, McGill University Health Center, McGill University, Montreal, Quebec, Canada.
    Women with Turner syndrome (TS) are at risk of premature ovarian failure. The objective of this retrospective study was to identify patients with TS who could be potential candidates for fertility preservation and to determine their present reproductive and fertility status. Criteria for fertility preservation included: (i) spontaneous menarche; (ii) confirmation by ultrasound examination of the presence of at least one normal ovary; and (iii) serum FSH concentrations below 40 IU/l. Read More

    Factors associated with bone density in young women with karyotypically normal spontaneous premature ovarian failure.
    Arch Gynecol Obstet 2009 Aug 23;280(2):177-81. Epub 2008 Dec 23.
    Departament of Obstetrics and Gynaecology, School of Medicine, State University of Campinas, Cidade Universitária Zeferino Vaz, Campinas, São Paulo, Brazil.
    Objective: To evaluate bone density and associated factors in women with premature ovarian failure (POF) compared to age-matched women with normal ovarian function.

    Methods: A cross-sectional study of 50 patients with POF undergoing bone mineral densitometry was conducted, compared to 50 women paired by age who menstruated regularly.

    Results: In women with POF, the mean bone mineral density measured was 1. Read More

    1 OF 3